Requests that the FDA declare that Buspirone HCl Oral Solution, 2.5 mg/mL, is suitable for submission as an ANDA.
🏛 Food and Drug Administration (FDA)FDA-2026-P-7531
Documents
6
Total comments
0
all analyzed
Comment status
Open
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
- Other· Jul 7, 2026No comment period
- Other· Jul 7, 2026No comment period